StayCurrentMD · Updated Favorable histology Wilms tumor risk stratification: Rationale for future Children’s Oncology Group clinical trials
Follow
Video53 s·Published Apr 2026

Updated Favorable histology Wilms tumor risk stratification: Rationale for future Children’s Oncology Group clinical trials

hosted by Dr. Jill Knepprath
Try
Intelligent Search· scoped to Wilms tumor · not medical adviceSearch the whole library →
What the experts said0 expert statements · 8 host summaries
Risk stratification for Wilms tumor has evolved many times over the years.
Host summaryJill Knepprath summarizing a resource · not cited in answers
The Children's Oncology Group published updated risk stratification for patients with favorable histology Wilms tumor in Nature in June 2025.
Host summaryJill Knepprath summarizing a resource · not cited in answers
The new risk stratification model includes biological and clinical features that were not in the first generation risk stratification.
Host summaryJill Knepprath summarizing a resource · not cited in answers
The new model changes some of the older features or gets rid of them altogether.
Host summaryJill Knepprath summarizing a resource · not cited in answers
Factors being added are loss of heterozygosity of 11P15, 1Q gain, and lymph node involvement.
Host summaryJill Knepprath summarizing a resource · not cited in answers
Tumor nephrectomy weight is no longer included in the risk stratification.
Host summaryJill Knepprath summarizing a resource · not cited in answers
The model modified how histology and age are used to stratify certain patients.
Host summaryJill Knepprath summarizing a resource · not cited in answers
More changes are expected in the future as ongoing COG trials produce more results.
Host summaryJill Knepprath summarizing a resource · not cited in answers